Target intelligence / Profile preview

Schistosome transient receptor potential melastatin channel (SmTRPM) (SmTRPM)

Target
SmTRPM
Molecular classification
Ion channel, Transient receptor potential channel, Melastatin-like TRP channel
01

Overview

Schistosome transient receptor potential melastatin (TRPM) channels, particularly the SmTRPM isoform, are essential ion channels in the parasitic flatworms that cause schistosomiasis. These channels are non-selective cation channels with high calcium permeability, playing a fundamental role in the parasite's neuromuscular regulation and the structural integrity of its tegument (Park et al., 2019, Science). For over 40 years, the drug praziquantel has been the primary treatment for schistosomiasis, but its molecular target remained elusive until SmTRPM was identified as its receptor. Praziquantel functions by binding to a specific pocket in the channel's voltage-sensor-like domain, acting as an allosteric activator that forces the channel into an open state (Le et al., 2021, Science). This activation causes a massive influx of calcium, leading to immediate muscle contraction, paralysis, and tegumental vacuolization. The resulting damage to the parasite's surface exposes it to the host's immune system, which ultimately leads to parasite clearance. Because SmTRPM is phylogenetically distinct from human TRPM channels, it serves as a highly specific and effective target for anthelmintic therapy with a high therapeutic index.

Other names
SmTRPMSmTRPM-PZQSchistosoma mansoni TRPM channelPraziquantel-sensitive TRPM channel
02

Mechanism of action

Praziquantel acts as a potent allosteric activator of the SmTRPM channel, inducing a rapid and sustained influx of calcium ions into the parasite (Park et al., 2019, Science; Le et al., 2021, Science).

03

Biological functions

Cation transportCalcium signalingNeuromuscular coordinationTegumental maintenance
04

Disease associations

SchistosomiasisInfection
05

Safety considerations

Emergence of drug-resistant parasite strainsLow efficacy against juvenile schistosomes (schistosomula)Host inflammatory response to dying parasites
06

Interacting drugs

Praziquantel
07

Biomarkers

Reduction in fecal egg count (Kato-Katz technique)Circulating anodic antigen (CAA) levelsCirculating cathodic antigen (CCA) levels

Beyond the preview

Go deeper on Schistosome transient receptor potential melastatin channel (SmTRPM) (SmTRPM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Schistosome transient receptor potential melastatin channel (SmTRPM) (SmTRPM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call